Codex DNA (TBIO): Earnings per share for the last twelve months
Telesis Bio, Inc. (TBIO) production facilities are operating at maximum efficiency, maintaining equipment in ideal condition. The company is scaling sales of BioXp systems to capture the DNA pharmaceutical market. The fundamental TTM net income per share metric confirms the current trend, where the value -30.63 indicates the profitability status. Reliable logistics for reagents and electronics complete the cycle, eliminating laboratory downtime.
Metric breakdowns and analytics for Telesis Bio Inc. (TBIO)
- stock price and consensus target price:
- stock exchange capitalization data:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Telesis Bio, Inc.|TBIO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Codex DNA|TBIO - Company Cumulative Debt|Debt to Book Value Telesis Bio, Inc.|TBIO - Company Long-Term Loans and Borrowings|Company Short-Term Debts Telesis Bio|Quick Liquidity telesisbio.com
- earnings and valuation multiples indicators:
TBIO - Company Profit|Projected Future Earnings Telesis Bio, Inc.|TBIO - Price to Earnings Ratio|Projected Price to Earnings Telesis Bio|TBIO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Telesis Bio, Inc.|TBIO - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Telesis Bio|TBIO - Earnings per share for the last twelve months|Quarterly EPS earnings growth telesisbio.com|TBIO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Telesis Bio, Inc.
- issuer revenue and sales details:
Basic company analysis:Telesis Bio, Inc. - TBIO
This indicator reflects the actual balance of market supply and demand, excluding speculative distortions. By analyzing the current trailing twelve-month EPS, an investor can observe the dynamics of specific return on equity. The metric is calculated as the sum of net income over the last four quarters divided by the current number of shares outstanding. For Telesis Bio, Inc. (TBIO), this figure is critical when scaling the delivery of BioXp systems. Growth in earnings per share would confirm the effectiveness of the expansion within the DNA synthesis sector.
Competing companies
Tempus AI - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters qiagen.com QGEN|Ionis (IONS) - Earnings per share for the last twelve months|RGEN - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RNA|CRSP: Earnings per share for the trailing year|Net earnings per share (EPS TTM) WGS|Earnings per share for the last twelve months RARE (ultragenyx.com)|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics)|Net earnings per share for the last four quarters Sarepta Therapeutics (SRPT)|TWST - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months 10x|NTLA (Intellia Therapeutics) - Net earnings per share for the last 12 months|stoketherapeutics.com - Earnings per share for the trailing year|BLFS (BioLife Solutions) - Net earnings per share (EPS TTM)|Wave Life Sciences Ltd (WVE) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Maze Tx (MAZE)|Sionna Corp - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) PRME (Prime Medicine, Inc.)|TSHA - Net earnings per share for the last 12 months|QURE: Net earnings per share for the last 12 months|Net earnings per share for the last four quarters MeiraGTx Holdings MGTX|RGNX (Regenxbio) - Net earnings per share for the last 12 months|SLDB: Earnings per share for the last four quarters|OCGN (Ocugen, Inc.) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months PACB|Net earnings per share (EPS TTM) BNTC|Net earnings per share for the last four quarters Design Therapeutics Inc|Earnings per share for the last twelve months Rocket Pharmaceuticals Inc RCKT|4D Molecular Corp (FDMT) - Net earnings per one share for the last twelve months|Lexeo - Net earnings per share (EPS TTM)|KRRO (Korro Bio, Inc.) - Earnings per share for the last 12 months|Editas Medicine (EDIT) - Earnings per share for the last twelve months|Earnings per share for the last 12 months SLN|PRQR (ProQR) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Codexis Bio|Net earnings per share for the last 12 months SGMO (Sangamo Therapeutics)|Earnings per share for the last four quarters NAUT|Net earnings per share (EPS TTM) MGX (Metagenomi)|Precision BioSciences Inc. (DTIL) - Net earnings per one share for the last twelve months|GBIO - Earnings per share for the last twelve months|BOLD: Earnings per share for the last twelve months|XCUR: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Imunon (IMNN)|Earnings per share for the last twelve months Phio Pharmaceuticals Corp|Mustang Bio Corp (MBIO) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) RNAZ|Net earnings per share for the last four quarters bionanogenomics.com|Earnings per share for the last twelve months Applied DNA Sciences APDN|Net earnings per share for the last four quarters bluebirdbio.com (BLUE)|IPA: Net earnings per share for the last 12 months|Earnings per share for the trailing year OMGA (Omega Therapeutics Inc)|OMIC: Net earnings per share (EPS TTM)|RGLS (Regulus) - Earnings per share for the last twelve months|SYRS (Syros Pharmaceuticals) - Net earnings per share (EPS TTM)|traconpharma.com (TCON) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Unity Biotechnology, Inc. (UBX)
